|
注册号: Registration number: |
ChiCTR2200062953 |
|
最近更新日期: Date of Last Refreshed on: |
2023-04-13 20:34:12 |
|
注册时间: Date of Registration: |
2022-08-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
FCD和TSC的单细胞核及空间转录组测序分析 |
|
Public title: |
Single nuclear RNA and spatial transcriptome sequencing of FCD and TSC |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
局灶皮层发育不良和结节性硬化的单细胞核转录组及空间转录组测序分析 |
|
Scientific title: |
Sequencing analysis of single nuclear transcriptome and spatial transcriptome in focal cortical dysplasia and tuberous sclerosis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘欣婷 |
研究负责人: |
杨光 |
|
Applicant: |
Liu Xinting |
Study leader: |
Yang Guang |
|
申请注册联系人电话: Applicant telephone: |
+86 15069099198 |
研究负责人电话:
Study leader's |
+86 13810192267 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lxting0531@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yangg301@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
28 Fuxing Road, Haidian District, Beijing |
Study leader's address: |
28 Fuxing Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院第一医学中心 |
||
|
Applicant's institution: |
The First Medical Center of PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院第一医学中心 |
||
|
Affiliation of the Leader: |
The First Medical Center of PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审第S2021-586-01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Chinese PLA General Hosptal |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-12-30 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Jiang Cao |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
28 Fuxing Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中国人民解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Medical Center of PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-finance |
||||||||||||||||||||||
|
研究疾病: |
局灶皮层发育不良、结节性硬化 |
||||||||||||||||||||||
|
Target disease: |
Focal cortical dysplasia and tuberous sclerosis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
我们的研究目的是整合正常与病变组织在单细胞和空间水平上的RNA、蛋白以及临床病理上的差异,找到与疾病相关的细胞类型或确定某个信号通路作为潜在靶标,根据单细胞转录组分析指导靶向用药,实现内科药物治疗代替外科手术治疗,减轻病人的痛苦,降低治疗成本和复发率,获得较好的预后。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of our research is to integrate the RNA, protein and clinicopathological differences between normal and diseased tissues at the single-cell and spatial levels, find the cell type related to the disease or determine a signal pathway as a potential target, guide the targeted drug use according to the single-cell transcriptome analysis, realize the medical drug treatment instead of surgical treatment, reduce the pain of patients, reduce the treatment cost and recurrence rate, and obtain a better prognosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.除可诊断为局灶皮层发育不良外,还有其他重大脑疾病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. In addition to the diagnosis of focal cortical dysplasia, there are other major brain diseases. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-09-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-09-01 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NO |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
使用电子病例记表单记录患儿资料,使用电子采集和管理系统管理原始资料。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Case Record Form were used to record the patient data, and Electronic Data Capture systems were used to manage the original data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |